key: cord-0015000-b3k2um6i
authors: Yu, Run
title: Successful Management of Pheochromocytoma and Thyroiditis With Fever by Telemedicine During the COVID-19 Pandemic
date: 2020-12-28
journal: Endocr Pract
DOI: 10.4158/1934-2403-26.9.1042
sha: 0c502fdf052f7eda9926e9f59922a70e7efffbbf
doc_id: 15000
cord_uid: b3k2um6i

nan

To the Editor:

The safety and effectiveness of telemedicine are established for common endocrine conditions such as diabetes (1) . My recent experience during the COVID-19 pandemic suggests that telemedicine is also applicable to managing rare and complex endocrine conditions.

The first patient was a 17-year-old male with pheochromocytoma. Six weeks before presentation, the patient had been found to have hypertension and tachycardia. Plasma metanephrine was <10 pg/mL (normal, 0 to 62 pg/ mL), but normetanephrine was 1,078 pg/mL (normal, 0 to 145 pg/mL). Computed tomography (CT) of the abdomen and pelvis revealed a 4.7 × 6.7 × 7.3 cm left adrenal mass ( Fig. 1 A) . He was referred to our institution. I reviewed the existing records and agreed with the pheochromocytoma diagnosis. To minimize exposure to severe acute respiratory syndrome coronavirus 2, I arranged an urgent telemedicine video visit, during which we discussed perioperative management and other issues (2) . The patient's mother was very involved in the care. She and I had email communications twice a week on the patient's blood pressure, pulse, and alpha and beta blocker doses. Phenoxybenzamine dose was titrated up to 30 mg twice a day and metoprolol dose to 100 mg twice a day. Three weeks after the telemedicine session, he underwent an uneventful left adrenalectomy.

The second patient was a 79-year-old male with thyroiditis and fever of unknown origin. One month before presentation, he had developed fever, shortness of breath, odynophagia, and weight loss. CT of chest did not find lung abnormalities. Thyroid-stimulating hormone was 0.02 mIU/L (normal, 0.40 to 4.50 mIU/L), free thyroxine was 3.0 ng/dL (normal, 0.8 to 1.8 ng/dL), thyroidstimulating immunoglobulin was <89% (normal, <140%), and C-reactive protein 162.1 mg/L (normal, <8 mg/L). Radioactive iodine thyroid uptake was 3% at 6 hours, and 2.7% at 24 hours. He was diagnosed with thyroiditis and was treated with ibuprofen and propranolol. Symptoms did not improve; his temperature ranged from 37.6°C to 39.7°C. CT findings of abdomen and pelvis were unremarkable and blood culture was negative. The patient's daughter was very involved in the care. At the first telemedicine session, I discussed that fever can be the main or even the only symptom of subacute thyroiditis but occult infections have to be further ruled out before corti- 

costeroid treatment is initiated (3) . As he did not respond to ibuprofen and propranolol and I could not do a physical examination, I ordered a fluorodeoxyglucose positron emission tomography (FDG PET) and thyroid ultrasound, otherwise not required for subacute thyroiditis diagnosis and management, which were done on the next day. FDG PET only showed diffuse and strong thyroid uptake with nonspecific uptake in hilar lymph nodes (Fig. 1 B) . Thyroid ultrasound did not find loculated fluid suggestive of infectious thyroiditis. Prednisone 40 mg daily with taper every 5 days was initiated 2 days after the first telemedicine session. Fever disappeared on the same day and odynophagia improved significantly. The patient was monitored with frequent telemedicine visits. On the fifth session, 2 weeks after prednisone treatment, he felt much better, was feverfree, and regained weight; thyroid function improved and C-reactive protein returned to normal. The 2 cases are unique in that they were rare and complex endocrine conditions presenting at atypically young or old age, their managements required timely decision making, and the potential interventions could be catastrophic if given inappropriately. The 2 cases suggest that, although in-person visits are preferable when feasible, telemedicine can be used to successfully manage rare and complex endocrine conditions, during the coronavirus disease 2019 pandemic and beyond, so long as the physician has expertise and the patient has adequate support and access to laboratories, imaging, and surgery. Further studies and experience are needed to arrive at a more definitive conclusion regarding telemedicine for managing rare and complex endocrine conditions.

The author has no multiplicity of interest to disclose. 

The impact of telehealth remote patient monitoring on glycemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials

Perioperative management of pheochromocytoma: the heart of the issue

Fever of unknown origin as a sole presentation of subacute thyroiditis in an elderly patient: a case report with literature review